nonsmall-cell lung cancer
Conditions
Interventions
control group:placebo
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) ASA I-II grade, aged >= 18 years. (2) Stage II or stage IIIA non-small cell lung cancer confirmed by histology. (3) Have measurable diseases evaluated according to RECIST version 1.1. (4) Confirm that it meets the requirements of R0 resection. (5) Good cardiopulmonary function. (6) Meet the conditions for receiving platinum-containing dual-drug chemotherapy. (7) Good blood and organ function.
Exclusion criteria
Exclusion criteria: (1) Have received any treatment for the current lung cancer, including chemotherapy or radiotherapy. (2) Receive opioid analgesia before surgery. (3) Known to carry EGFR mutation or ALK gene translocation. (4) There are locally advanced unresectable diseases and metastatic diseases. (5) Has suffered from any disease that requires systemic treatment with corticosteroids or other immunosuppressive drugs in the 14 days before randomization. (6) A history of active autoimmune diseases or autoimmune diseases that may recur. (7) History of interstitial lung disease, non-infectious pneumonia or poorly controlled diseases (including pulmonary fibrosis, acute lung disease, etc.). (8) Severe chronic or active infections require systemic antibacterial, antifungal or antiviral treatment, including tuberculosis infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Perioperative opioid dosage; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of POD;pain score;Inflammatory factor levels; | — |
Countries
China
Contacts
Public ContactKaiyuan Wang
Tianjin Medical University Cancer Institute and Hospital
Outcome results
None listed